Abstract
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.
MeSH terms
-
Animals
-
Antibodies, Bispecific / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bendamustine Hydrochloride / therapeutic use
-
Drug Development
-
Humans
-
Immunoconjugates / therapeutic use
-
Immunotherapy, Adoptive / methods*
-
Lenalidomide / therapeutic use
-
Lymphoma, Large B-Cell, Diffuse / therapy*
-
Molecular Targeted Therapy / methods
-
Rituximab / therapeutic use
Substances
-
Antibodies, Bispecific
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Immunoconjugates
-
Rituximab
-
Bendamustine Hydrochloride
-
Lenalidomide
-
polatuzumab vedotin
-
tafasitamab